The number of people with COVID-19 has been rising rapidly in China in recent weeks, and there are concerns that the government in Beijing could consider reviving its strict lockdown policies again. A surge in COVID-19 there means other parts of the world could soon face similar problems. And if that happens, demand for COVID-19 vaccines such as  's (NASDAQ: MRNA) Spikevax could reaccelerate.

Does that mean that this would be an opportune time to buy shares of the biotech company? Let's take a look.

COVID-19 cases have been surging in China, largely due to the spread of the omicron XBB variants. Earlier this year, these variants became the most prevalent ones in the U.S. as well.

Continue reading

Source Fool.com